Mylan NV shares slumped 1.3% in after-hours trade Friday afternoon after the company said that a previously announced voluntary recall of EpiPens would include U.S. EpiPens and EpiPen Jrs. The recall was initiated after two reports from outside of the U.S. of the EpiPen failing to activate “due to a potential defect in a supplier component,” Mylan said. The two reports came from a single lot that was previously recalled, Mylan said, but the company was expanding the recall to 13 U.S. lots distributed in the U.S. between December 2015 and July 2016 as a “precautionary measure out of an abundance of caution.” Pfizer’s Meridian Medical Technologies manufactured the recalled EpiPens and Mylan distributed them. Mylan said it plans to replace the recalled EpiPens at no cost to patients. Mylan shares have risen 2.0% over the last three months, compared with a 5.5% rise in the S&P 500 .
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News